Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Study Examines 'Elite' Group Of HIV-Positive People Who Appear 'Protected' From Developing AIDS
An international contingent of nearly 500 researchers and physicians are taking part in the International HIV Controllers Study, which is examining "the phenomenon," in which certain people living with HIV seem "somehow protected from AIDS," the Washington Post reports. Fewer "than one in every 300 cases, or perhaps 5,000 of the more than 1 million infected Americans" living with HIV are deemed ""elite controllers" because their ability to combat the virus puts them in exceptional company among infected individuals," according to the Post. The article states, "No one knows how their bodies keep AIDS at bay. Are their immune systems exceptionally strong and effective? Do they possess some genetic trait that protects them? Or does a combination of still-unknown factors set them apart?" Researchers anticipate that studying the T cell levels - which helps determine the progression to AIDS - of the elite controllers, will enable them "to uncover what shields these rare few from AIDS. And perhaps in the process they"ll find a way to safeguard everyone else as well," the Post reports (Slack, 7/7). Don't forget to buy zoloft online no prescription.

HHS Purchases Additional H1N1 Vaccine Ingredients
HHS Secretary Kathleen Sebelius announced today that the department will commit $884 million to purchase additional supplies of two key ingredients for potential H1N1 vaccine to further prepare the nation for a potential resurgence of the 2009 H1N1 virus.

generic viagra online


News of the day
Economist Examines 'Snail-Fever' In China
The Economist examines schistosomiasis in China. The disease, which is also called snail-fever, is the "world"s second-most prevalent tropical disease after malaria, affecting 207 million people of whom 726,000 are Chinese, according to the most recent official figures, from 2004," the Economist reports.
Endocrinology

CytRx's INNO-206 Demonstrates Statistically Significant Tumor Shrinkage In Animal Trial For Breast Cancer

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that its investigational cancer drug INNO-206 caused a dramatic destruction of implanted tumors in an experimental animal model of breast cancer, performing considerably better than the broadly used and generally effective chemotherapeutic drug doxorubicin. In addition to improved efficacy in this animal trial, INNO-206 was comparable in toxicity with doxorubicin based on animal body-weight loss. CytRx has exclusive worldwide rights to INNO-206, a proprietary derivative of doxorubicin. The pro-drug INNO-206 is designed to allow controlled release of doxorubicin and to specifically target the delivery of drug to tumors throughout the body, which could prove more effective and less toxic in cancer patients than doxorubicin. INNO-206 has previously demonstrated safety and tolerability, and optimal dosing has been evaluated, in a Phase I clinical trial. In the animal trial - conducted under the direction of INNO-206 inventor Felix Kratz, Ph.D., Department of Medical Oncology, Clinical Research, at the Tumor Biology Center in Freiburg, Germany - human breast tumor cells were implanted in mice with compromised immune systems to avoid tumor rejection. Seven to eight animals were randomly assigned into each of three experimental groups receiving intravenous injections with either a maximum tolerated dose of INNO-206, a maximum tolerated dose of doxorubicin, or a control solution lacking either compound. At the end of the experiment 43 days after implantation, tumors had increased in volume by an average of approximately 2.7-fold in the control group while tumor growth was marginally inhibited in the doxorubicin group; increasing in volume by approximately 1.9-fold in a result that did not reach statistical significance. By contrast, tumors in the group treated with INNO-206 shrank to approximately one-half their initial volume. The decrease in final tumor volume in INNO-206-treated animals was statistically significant (pAbout Breast Cancer Breast cancer is the most common cancer among women in the U.S., with more than 192,000 new cases of invasive breast cancer expected to be diagnosed this year, according to American Cancer Society estimates. More than 40,000 deaths are expected to be attributed to breast cancer in the U.S. in 2009, making it the second leading cause of cancer death in U.S. women. The chance of a woman having invasive breast cancer some time during her life is about one in eight. About INNO-206 INNO-206 is a prodrug of the commonly prescribed chemotherapeutic doxorubicin and was designed to reduce adverse events by controlling release and preferentially targeting the tumor. In a Phase 1 study, doses were administered at up to six times the standard dosing of doxorubicin without an increase in observed side effects over those historically seen with doxorubicin. The Company is evaluating options for a possible Phase 2 clinical trial. CytRx Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009